Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1990 1
1992 1
1993 1
1994 1
1997 1
1999 1
2000 1
2001 1
2002 1
2003 2
2004 3
2005 2
2007 1
2008 1
2009 1
2010 2
2013 1
2014 1
2015 2
2018 1
2019 1
2020 5
2021 3
2022 1
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Results by year

Filters applied: . Clear all
Page 1
Manipulation of epitope function by modification of peptide structure: a minireview.
Hudecz F. Hudecz F. Biologicals. 2001 Sep-Dec;29(3-4):197-207. doi: 10.1006/biol.2001.0305. Biologicals. 2001. PMID: 11851316 Review.
We have explored various approaches to modify the immunrecognition of linear peptides representing sequential or continuous topographic B-cell or T-cell epitopes. ...To increase antigenicity and immunogenicity we have prepared cyclic and chimaeric peptide variants as well …
We have explored various approaches to modify the immunrecognition of linear peptides representing sequential or continuous topograph …
Immunogenicity of neutralizing epitopes on multiple-epitope vaccines against HIV-1.
Lu Y, Xiao Y, Ding J, Dierich M, Chen YH. Lu Y, et al. Int Arch Allergy Immunol. 2000 Jan;121(1):80-4. doi: 10.1159/000024300. Int Arch Allergy Immunol. 2000. PMID: 10686512
Both antisera induced by both multiple-epitope vaccines interacted with the recombinant soluble gp41 (rgp41), but did not bind two control peptides. In comparison with both epitope vaccines, the rgp160 subunit vaccine could induce weak epitope-specific antibo …
Both antisera induced by both multiple-epitope vaccines interacted with the recombinant soluble gp41 (rgp41), but did not bind …
Phase I Study of Multiple Epitope Peptide Vaccination in Patients With Recurrent or Persistent Cervical Cancer.
Hasegawa K, Ikeda Y, Kunugi Y, Kurosaki A, Imai Y, Kohyama S, Nagao S, Kozawa E, Yoshida K, Tsunoda T, Nakamura Y, Fujiwara K. Hasegawa K, et al. J Immunother. 2018 May;41(4):201-207. doi: 10.1097/CJI.0000000000000214. J Immunother. 2018. PMID: 29432282 Clinical Trial.
All patients had recurrent or persistent disease and had failed to respond to or were intolerant to prior standard chemotherapy. Peptides derived from forkhead box protein M1 (FOXM1), maternal embryonic leucine zipper kinase (MELK), Holliday junction-recognition protein, a …
All patients had recurrent or persistent disease and had failed to respond to or were intolerant to prior standard chemotherapy. Peptides …
Cluster binding studies with two anti-Thomsen-Friedenreich (anti-core-1, CD176, TF) antibodies: Evidence for a multiple TF epitope.
Flechner A, Butschak G, Löffler A, Rühmann J, Nishimura SI, Dölling R, Purfürst B, Goletz S, Danielczyk A, Karsten U. Flechner A, et al. Int Immunopharmacol. 2019 Jul;72:186-194. doi: 10.1016/j.intimp.2019.03.058. Epub 2019 Apr 15. Int Immunopharmacol. 2019. PMID: 30999209
We have examined the type of clusters recognized by two anti-Thomsen-Friedenreich (TF, core-1, CD176) IgM antibodies, NM-TF1 and NM-TF2, using several different sets of TF-carrying synthetic glycoconjugates in ELISA experiments. To our surprise, the single most important f …
We have examined the type of clusters recognized by two anti-Thomsen-Friedenreich (TF, core-1, CD176) IgM antibodies, NM-TF1 and NM-T …
Safety and antibody immune response of CHP-NY-ESO-1 vaccine combined with poly-ICLC in advanced or recurrent esophageal cancer patients.
Ishikawa T, Kageyama S, Miyahara Y, Okayama T, Kokura S, Wang L, Sato E, Yagita H, Itoh Y, Shiku H. Ishikawa T, et al. Cancer Immunol Immunother. 2021 Nov;70(11):3081-3091. doi: 10.1007/s00262-021-02892-w. Epub 2021 Mar 22. Cancer Immunol Immunother. 2021. PMID: 33751208 Clinical Trial.
The nanoparticle complex of cholesteryl pullulan (CHP) and NY-ESO-1 antigen protein (CHP-NY-ESO-1) presents multiple epitope peptides to MHC class I and II pathways, leading to CD8(+) and CD4(+) T cell responses. ...In a mouse model, adding anti …
The nanoparticle complex of cholesteryl pullulan (CHP) and NY-ESO-1 antigen protein (CHP-NY-ESO-1) presents multiple …
Enhanced detection of human immunodeficiency virus type 1 (HIV-1) Nef-specific T cells recognizing multiple variants in early HIV-1 infection.
Malhotra U, Li F, Nolin J, Allison M, Zhao H, Mullins JI, Self S, McElrath MJ. Malhotra U, et al. J Virol. 2007 May;81(10):5225-37. doi: 10.1128/JVI.02564-06. Epub 2007 Feb 28. J Virol. 2007. PMID: 17329342 Free PMC article.
The greatest frequency of responses spanned Nef amino acids 65 to 103 and 113 to 147, with multiple epitope variants being recognized. Detection of both the epitope domain number and the response magnitude was enhanced using the PTE peptides. On average, we d …
The greatest frequency of responses spanned Nef amino acids 65 to 103 and 113 to 147, with multiple epitope variants being rec …
Protective immunity following vaccination with a recombinant multiple-epitope protein of bovine herpesvirus type I in a rabbit model.
Wen X, Tong X, Wang M, Wang J, Ni H, Ran X. Wen X, et al. Appl Microbiol Biotechnol. 2020 Apr;104(7):3011-3023. doi: 10.1007/s00253-020-10420-6. Epub 2020 Jan 31. Appl Microbiol Biotechnol. 2020. PMID: 32002602
Bovine herpesvirus type 1 (BoHV-1) causes considerable economic losses to the cow industry. ...The envelope glycoproteins of BoHV-1 induce a protective immune response. In this work, selected epitopes on glycoproteins gD, gC, and gB were constructed in tripli …
Bovine herpesvirus type 1 (BoHV-1) causes considerable economic losses to the cow industry. ...The envelope glycoproteins of B …
Epitope specificity of cross-clade neutralizing sera from Chinese HIV-1-positive individuals.
Song H, Chu Y, Zhang H, Wang X, Zhang T, Qiu M, Wu H, Wu Z. Song H, et al. Scand J Immunol. 2013 Oct;78(4):357-70. doi: 10.1111/sji.12091. Scand J Immunol. 2013. PMID: 23808939 Free article.
Here, we screened 80 Chinese HIV-1-positive sera against a minipanel of pseudoviruses representing various circulating HIV-1 subtypes in China and identified 8 cross-clade neutralizing sera (CNsera). Immunological characterization of the sera showed that gp120-targe …
Here, we screened 80 Chinese HIV-1-positive sera against a minipanel of pseudoviruses representing various circulating HIV-1 s …
Anti-cancer immunotherapy using cancer-derived multiple epitope-peptides cocktail vaccination clinical studies in patients with refractory/persistent disease of uterine cervical cancer and ovarian cancer [phase 2].
Takeuchi S, Kagabu M, Shoji T, Nitta Y, Sugiyama T, Sato J, Nakamura Y. Takeuchi S, et al. Oncoimmunology. 2020 Nov 11;9(1):1838189. doi: 10.1080/2162402X.2020.1838189. Oncoimmunology. 2020. PMID: 33235818 Free PMC article. Clinical Trial.
Enrollees must be refractory/persistent disease for usual treatments with Human Leukocyte Antigen-A*0201 or A*2402. The targets were epitope peptides obtained from driver genes in surviving pathways as follows: for CC A*0201, peptides from Up Regulating Lung Cancer …
Enrollees must be refractory/persistent disease for usual treatments with Human Leukocyte Antigen-A*0201 or A*2402. The targets were epitope …
First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors.
Ishihara M, Tono Y, Miyahara Y, Muraoka D, Harada N, Kageyama S, Sasaki T, Hori Y, Soga N, Uchida K, Shiraishi T, Sato E, Kanda H, Mizuno T, Webster GA, Ikeda H, Katayama N, Sugimura Y, Shiku H. Ishihara M, et al. Cancer Immunol Immunother. 2020 Apr;69(4):663-675. doi: 10.1007/s00262-020-02483-1. Epub 2020 Jan 24. Cancer Immunol Immunother. 2020. PMID: 31980914 Free PMC article. Clinical Trial.
Cholesteryl pullulan (CHP) is a novel antigen delivery system. CHP and New York esophageal squamous cell carcinoma 1 (NY-ESO-1) antigen complexes (CHP-NY-ESO-1) present multiple epitope peptides to the MHC class I and II pathways. ...In a …
Cholesteryl pullulan (CHP) is a novel antigen delivery system. CHP and New York esophageal squamous cell carcinoma 1 (NY-ESO-1 …
36 results